Core Viewpoint - Quantum BioPharma Ltd. is actively participating in two upcoming conferences to engage with institutional investors and showcase its innovative biopharmaceutical solutions [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis, currently in preclinical development [4]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% [4]. Conference Participation - Jason Sawyer, the Head of Finance and M&A, will represent Quantum BioPharma at the Sidoti Micro-Cap Conference on May 21, 2025, and the A.G.P. Virtual Healthcare Conference on May 22, 2025 [2][3]. - At the Sidoti Micro-Cap Conference, Sawyer will host one-on-one meetings with institutional investors and deliver a webcast presentation [2][3].

Core Viewpoint - Quantum BioPharma Ltd. has completed dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302, aimed at treating Multiple Sclerosis, which is a significant step towards submitting an IND application to the US FDA [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, including Multiple Sclerosis [3]. - The company is advancing its lead compound, Lucid-MS, which is a patented new chemical entity designed to prevent and reverse myelin degradation, a key mechanism in Multiple Sclerosis [3]. Development Progress - The completion of toxicity studies for Lucid-21-302 brings the company closer to initiating a Phase 2 trial for Multiple Sclerosis [2]. - The company plans to submit the IND application for Lucid-21-302 before the end of the year [2]. Strategic Investments - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition, which is involved in the OTC version of its product unbuzzd™. The agreement includes a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [3]. - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3].

Company Overview - Quantum BioPharma Ltd. is hosting a Business Update Conference Call on May 6, 2025, at 04:30 PM ET, led by its Founder and CEO, Zeeshan Saeed, and Head of Finance and M&A, Jason Sawyer [1][5]. Forward-Looking Statements - The conference call may include forward-looking statements that represent the company's current judgment on future events, which are subject to risks and uncertainties that could lead to actual results differing materially [2][4]. - Participants are cautioned not to place undue reliance on these forward-looking statements, as they reflect opinions only as of the date of the presentation [3].

Core Viewpoint - Quantum BioPharma Ltd. has filed an amended complaint alleging market manipulation by several banks, seeking damages exceeding $700 million USD due to the alleged manipulation of its stock price through "spoofing" techniques from January 2020 to August 2024 [1][2][3]. Group 1: Legal Proceedings - The amended complaint was filed on May 1, 2025, in response to a Motion to Dismiss from the banks [1]. - The lawsuit claims that CIBC World Markets and RBC Dominion Securities, among others, violated the Securities Exchange Act of 1934 [1][2]. - The law firms Christian Attar and Freedman Normand Friedland LLP are representing the company on a contingency basis, alleviating financial pressure for legal costs [2]. Group 2: Allegations of Market Manipulation - The complaint alleges that the defendants engaged in "spoofing" techniques that artificially depressed Quantum BioPharma's stock price [2]. - The company asserts that the stock was trading over $460 USD per share in January 2020, with a market capitalization nearing $1 billion USD [3]. - Quantum BioPharma believes that additional banks and brokers may also be involved in the alleged manipulation but will not disclose their names until more evidence is gathered [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [7]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [8]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which includes a royalty agreement on sales from its product unbuzzd™ [8].

TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), today announced its licensee – Celly Nutrition Corporation ("Celly Nutrition"), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – has secured a landmark partnership with the Asian American Trade Associations Council ("AATAC") to expand the retail availability of unbuzzd™, increase ...

Core Viewpoint - Quantum BioPharma Ltd. announced the launch of its anti-hangover beverage, unbuzzd, in Puerto Rico through its licensee Celly Nutrition and distribution partner FUSION Distribution Group, aiming to expand its market presence in the Caribbean region [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse [11]. - Celly Nutrition Corporation is a public issuer specializing in wellness and recovery supplements, with unbuzzd developed by a team in pharmacology and medicine [7]. - FUSION Distribution Group is a leading distributor of health-conscious food and beverages in Puerto Rico and the Caribbean, with a strong network including major retailers [4][6]. Product Details - unbuzzd is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, supported by a double-blind placebo-controlled study [3][8]. - The product is available in convenient "On-the-Go Powder Stick Packs" and can be purchased in various pack sizes [9]. Distribution Strategy - FUSION will distribute unbuzzd across various retail channels in Puerto Rico, including grocery stores, pharmacies, and hospitality venues, aiming for widespread consumer accessibility [5][4]. - The partnership with FUSION is seen as a significant milestone for Celly Nutrition in expanding unbuzzd's retail availability [5]. Financial Arrangement - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and will receive a 7% royalty on unbuzzd sales until reaching $250 million, after which the royalty will decrease to 3% [11].

"We are very excited about the potential of this novel PET biomarker to directly visualize and measure demyelination in the central nervous system", said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. "We expect that this biomarker will be an important diagnostic tool in future MS trials investigating therapies that can prevent demyelination and promote remyelination. This is very relevant to our Lucid-MS clinical development program as Lucid-MS has been shown ...

EXHIBIT 99.1 Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the ...

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the "March 7 NR"). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for $2,42 ...

Financial Performance - The company reported its financial results for the fiscal year ended December 31, 2024, with detailed analysis available in the 2024 Annual MD&A[514]. - No significant trends or uncertainties are expected to adversely affect net revenues or profitability for the period from January 1, 2024, to December 31, 2024[517]. - The total cumulative return for Quantum BioPharma Ltd. was C$3.63 as of December 31, 2024, compared to C$100 on December 31, 2020, indicating a significant decline in shareholder value over the period[559]. Executive Leadership - The company’s executive team includes Anthony Durkacz as Co-Executive Chairman and Zeeshan Saeed as CEO, with a focus on strategic leadership[520]. - Donal Carroll resumed the role of CFO on August 30, 2024, after previously serving in various financial leadership roles[527]. - The company has not disclosed any new products or technologies in the current report, but ongoing R&D efforts are highlighted[516]. Compensation and Governance - The company has a compensation philosophy aimed at aligning executive pay with performance, with specific disclosures for NEOs for the year ended December 31, 2024[538]. - The executive compensation program for the year ended December 31, 2024, included base compensation, potential annual incentive awards, Options, RSUs, and PSUs[541]. - For 2024, Zeeshan Saeed, CEO, received a total compensation of $583,685, which included a salary of $218,635 and share-based awards of $365,050[563]. - The Compensation, Nominating and Governance Committee evaluates executive performance against the Company's goals and compares it with other similar-sized reporting issuers[546]. - The Company aims to provide a competitive compensation package to attract and retain qualified executives while linking compensation to corporate performance[543]. - The Company does not have fixed criteria for determining compensation, opting instead for a contextual analysis based on various factors[547]. - The Board believes that the compensation levels for directors and executive officers should not be directly compared to market performance due to external factors affecting stock prices[559]. Board Structure and Responsibilities - The company’s board includes members with extensive experience in healthcare, finance, and strategic management, enhancing its governance[520][529]. - There are no family relationships among the executive officers or directors, ensuring a professional governance structure[536]. - The Board consists of seven members, with four being independent directors[598][599]. - The Board is responsible for overseeing the development of the Company's strategic plan and ensuring management meets corporate objectives[595]. - The Board has adopted a Code of Conduct and Ethics to guide ethical business conduct and compliance with applicable laws[617]. - The Board's mandate includes assessing the effectiveness of its committees and individual directors[607]. - The Compensation, Nominating and Governance Committee is responsible for recommending candidates for Board nomination and ensuring the Board's effectiveness[640][641]. Employee Relations and Workforce - As of December 31, 2024, the company had seven full-time employees, a decrease from 17 in 2022, with research and development staff reduced from 12 to 2[655][656]. - The company maintains good relations with its employees, with no employees represented by collective bargaining agreements[655]. - The company does not have any women on the Board or in executive officer positions, representing 0%[654]. - The company has not adopted a term limit for directors, considering the benefits of renewal in the context of the Board's needs[649]. - The company does not have specific targets for appointing women to the Board or in executive officer positions[653]. Risk Management - The company operates primarily in Canada, the United States, and Australia, exposing it to foreign currency risk without using financial derivative instruments to manage this risk[797]. - The company holds certain cryptocurrency assets, which exposes it to significant volatility and regulatory risks in the cryptocurrency markets[799]. Audit and Compliance - The Audit Committee meets quarterly to review and approve the unaudited interim and annual audited financial statements, ensuring management fulfills its financial reporting responsibilities[627][628]. - The Audit Committee pre-approved all audit services provided by independent auditors for the fiscal year ended December 31, 2024[637]. - The company established a 401(k) plan on January 31, 2021, which was terminated on December 31, 2021, and currently has no pension plans[579]. - The annual cost for directors' and officers' liability insurance was C$108,000 for the year ended December 31, 2024[588]. - Each director is entitled to an annual retainer of C$50,000, which can be paid in cash, share-based compensation, or a combination of both[591].